Search

Canosimibe

Canosimibe has a monoisotopic molecular weight of 809.43 Da. … Canosimibe is under investigation in clinical trial NCT00729027 (Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia).

Nirogacestat

It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase … [A262561] Nirogacestat was approved under the brand name OGSIVEO on November 27, 2023, by the FDA for the treatment of adult patients with progressing desmoid tumors who require systemic treatment.

Chromous sulfate

Maytansine

Maytansine has a monoisotopic molecular weight of 691.29 Da. … Maytansine is under investigation in clinical trial NCT04189211 (A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients).

Crotalus adamanteus antivenin

They are large, heavy-bodied snakes with large, broad heads with two light lines on the face [L2877]. … The majority of people bitten are males and about 50% occur in the age group of 18 to 28 [F116].

Influenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen

This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

Influenza B virus B/Wisconsin/1/2010 recombinant hemagglutinin antigen

This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (propiolactone inactivated)

This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

Influenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) antigen (propiolactone inactivated)

This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (propiolactone inactivated)

This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen